Finanzen von Enliven Therapeutics Inc (ELVN)ELVNEnliven Therapeutics Inc

Evaluating the bottom line, Enliven Therapeutics, Inc. maintains a gross margin of N/A. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at N/A, while the net margin is N/A. These profitability ratios, combined with a Return on Equity (ROE) of -15.31%, provide a clear picture of how effectively ELVN converts its operational activities into shareholder value.

In the context of the broader market, ELVN competes directly with industry leaders such as RLAY and ADPT. With a market capitalization of $4.24B, it holds a significant position in the sector. When comparing efficiency, ELVN's gross margin of N/A stands against RLAY's 100.00% and ADPT's 71.23%. Such benchmarking helps identify whether Enliven Therapeutics, Inc. is trading at a premium or discount relative to its financial performance.

Enliven has shown significant volatility in earnings, with a net income loss of $32.5 million in Q2 2026 and a negative EPS of -0.49, indicating challenges in achieving profitability.